The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
Shannon Puhalla
Consultant or Advisory Role - Celldex; MedImmune; Pfizer
Sharon Wilks
Consultant or Advisory Role - Eisai
Adam Brufsky
Consultant or Advisory Role - Eisai; Roche
Joyce O'Shaughnessy
Consultant or Advisory Role - Eisai
Lee Steven Schwartzberg
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Erhan Berrak
Employment or Leadership Position - Eisai
James Song
Employment or Leadership Position - Eisai
David Cox
Employment or Leadership Position - Eisai
Linda T. Vahdat
Consultant or Advisory Role - Eisai